...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Archives of Pathology & Laboratory Medicine >Application of Immunohistochemistry to the Diagnosis of Primary and Metastatic Carcinoma to the Lung
【24h】

Application of Immunohistochemistry to the Diagnosis of Primary and Metastatic Carcinoma to the Lung

机译：免疫组化在肺癌原发性和转移性癌诊断中的应用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT: Immunohistochemistry is a very valuable and often used tool in the differential diagnosis of lung carcinomas whether primary or secondary to the lung. The most useful application is in distinguishing primary lung tumors from metastatic tumors to the lung from common sites (colon, breast, prostate, pancreas, stomach, kidney, bladder, ovaries, and uterus). Immunohistochemistry also aids in the separation of small cell carcinoma from non-small cell carcinoma and carcinoids particularly in small biopsy specimens limited by artifact. Although there is no "lung-specific tumor marker," with the help of a relatively restricted marker, thyroid transcription factor 1, it is possible to separate a lung primary from a metastasis with a reasonable degree of certainty. Another lung-specific marker on the horizon is napsin A, which appears to complement thyroid transcription factor 1 in defining a lung primary. OBJECTIVE: To present a practical review and to critique commonly used markers in the differential diagnosis of lung neoplasms and to list valuable immunohistochemical prognostic markers that the pathologist is called on to perform and interpret. DATA SOURCES: A comprehensive PubMed data search and personal practical experience. CONCLUSIONS: With a panel of immunohistochemical markers, it is possible to distinguish or narrow down most lung neoplasms and separate them into meaningful therapeutic categories. In the future as more proteomic and genomic data surface, immunohistochemical markers to newly discovered antigens may become a routine part of prognostication.
机译：背景：免疫组化是一种非常有价值的且经常用于肺癌的鉴别诊断的工具，无论是原发性还是继发于肺癌。最有用的应用是区分原发性肺部肿瘤和转移性肿瘤，以及常见部位（结肠，乳房，前列腺，胰腺，胃，肾，膀胱，卵巢和子宫）。免疫组织化学还有助于从非小细胞癌和类癌中分离出小细胞癌，特别是在受假象限制的小活检样本中。尽管没有“肺特异性肿瘤标志物”，但在相对受限的标志物甲状腺转录因子1的帮助下，有可能以合理的确定性从转移中分离出肺原发灶。即将出现的另一种肺特异性标记物是napsin A，其可在定义肺原发性疾病时补充甲状腺转录因子1。目的：对肺癌的鉴别诊断进行实用的回顾和批评，并列出有价值的免疫组织化学预后标志物，以供病理学家检查和解释。数据来源：全面的PubMed数据搜索和个人实践经验。结论：利用一组免疫组织化学标记物，可以区分或缩小大多数肺部肿瘤并将其分为有意义的治疗类别。将来，随着蛋白质组学和基因组数据的增多，针对新发现的抗原的免疫组化标记可能会成为预后的常规部分。

著录项

  • 来源
    《Archives of Pathology & Laboratory Medicine》 |2008年第3期|p.384-395|共12页
  • 作者

    Jaishree Jagirdar;

  • 作者单位

    Jaishree Jagirdar, MDAccepted for publication November 9, 2007.From the Department of Pathology, University of Texas Health Science Center at San Antonio.The author has no relevant financial interest in the products or companies described in this article.Reprints: Jaishree Jagirdar, MD, Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr, San Antonio, TX 78230 (e-mail: Jagirdar@uthscsa.edu).;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号